Breast CANcer Risk Assessment in Younger Women: BCAN-RAY

Breast Cancer Female Clinical Trial

— BCAN-RAY  

Official title:

A Case Control Study of Women Aged 30-39 to Augment Breast Cancer Risk Prediction and Assess Acceptability and Preference of a Systematic Risk Prediction Approach Through Primary Care

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05305963
• Other study ID #: 309424
• Status: Recruiting
• Start date: January 31, 2023
• Est. completion date: May 31, 2025

Study information

• Verified date: July 2023
• Source: Manchester University NHS Foundation Trust
• Contact: Stephanie Ng
• Phone: 0161 291 4408
• Email: stephanie.ng[@]manchester.ac.uk
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The overarching aim of the proposed research is to develop a comprehensive breast cancer risk assessment strategy for women aged 30-39 years.

There are three main objectives to the study.

Objective 1 - Mammographic Density and Risk To define the magnitude of BC risk associated with MD in women aged 30-39 and facilitate its incorporation into risk prediction models.

Objective 2 - Psychological impact

To examine the feasibility of a strategy to offer breast cancer risk-assessment to diverse ethnic and socioeconomic populations of women in their 30s, assessing:

• Potential benefits and harms

• Impact on health inequalities

• Acceptability

Objective 3 - DNA Methylation substudy To explore the potential of DNA Methylation (DNAme) signatures from self-obtained cervical samples to further refine risk prediction algorithms

Description:

Breast cancer (BC) is the most common cause of female cancer death worldwide. Incidence and mortality rates rise exponentially from age 30-50 (figure; CRUK 2021) and BC is the most common of any cause of death in women in this age group.

The reasons for this dramatic increase in incidence in young women are not well understood and contrast with other endocrine sensitive organs (endometrium and ovary) in which cancer rates increase much later in life. Cervical cancer mortality reduced dramatically, including in young women, following the introduction of widespread screening starting in women in their 20s. This was aided by the identification of key risk factors (sexual activity and HPV infection), direct access to the cervical epithelium and an identifiable premalignant stage. In contrast, in the UK, a strong family history (FH) of BC is the only trigger for BC risk assessment and the opportunity for women aged under 50 to access genetic testing, enhanced screening and primary prevention programmes (NICE 2013). However, in women diagnosed with breast cancer under the age of 40 at least 65% do not have a FH, the proportion increasing further in those diagnosed in older age cohorts (Copson 2018; Eccles 2015).

In addition, BC in young women is more frequently lethal, due to a combination of later stage at presentation, due in part to the lack of screening programmes, and a greater proportion of women developing more aggressive BC subtypes (Colleoni 2002; Paik 2006). The reliance on FH belies the progress over recent decades in the identification of additional BC risk factors including those related to reproductive/lifestyle influences, polygenic risk scores (PRS) and mammographic density (MD) and their incorporation into robust risk prediction algorithms.

The Predicting Risk Of Cancer At Screening (PROCAS NIHR Ref: RP-PG-0707-10031) study recruited over 58,000 women (aged 47-73y) from the Greater Manchester National Health Service Breast Screening Programme (NHSBSP) and showed that it is possible to accurately estimate a woman's individual risk of developing BC through self-report questions and assessment of MD and PRS (van Veen 2018). Using FH alone, only 3.7% of women were identified as being at moderate to high risk of BC according to NICE guidelines (NICE 2017) whereas the comprehensive approach above classified 18% as at least moderate risk and with excellent calibration (observed to expected OR 0.98; 95%CI 0.69-1.28; van Veen 2018). At least 30% of the BC's across the whole population developed in this cohort, a value that exceeded 40% when additional validated single nucleotide polymorphisms (SNPs) were incorporated into the PRS (Brentnall 2020). Women in the moderate/high risk groups can then be offered enhanced screening with predicted improvements in survival (Evans 2014) and preventive medications that result in fewer BC and are cost saving to the NHS (NICE 2017). A follow-on study has been developed to assess the feasibility and acceptability of integrating this approach into the NHSBSP (French 2020).

The current study has been designed to test whether a similar approach is acceptable in women aged 30-39 years and through use of a case control design will assess the impact of mammographic density on BC risk in women of this age. To facilitate the approach, we have developed a web-based application (WBA) based on the Tyrer-Cuzick (T-C) algorithm (see section 1.2 below) and an Automated Low Dose Risk Assessment Mammography (ALDRAM) technique.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: May 31, 2025
• Est. primary completion date: May 1, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 30 Years to 39 Years

Eligibility

4.1 Inclusion Criteria 4.1.1 Main study

The following criteria must be met for entry to the main case control study:

4.1.1.1 Cases

• Born biologically female

• Aged 30-39 years when diagnosed with breast cancer

• Able to provide informed consent

4.1.1.2 Controls

• Born biologically female

• Aged 30-39 years

• Able to provide informed consent

4.1.2 Acceptability Substudy All control participants that are eligible for the main study are eligible for inclusion in the acceptability substudy.

4.1.3 DNA methylation substudy

Case participants will only be eligible for the DNAme substudy if they fulfill all eligibility criteria for the main study and the following inclusion criterion:

• Yet to receive any systemic therapy for early breast cancer (chemotherapy, endocrine therapy or targeted therapy eg trastuzumab (Herceptin))

All control participants are eligible for the DNAme substudy if eligibility criteria are met for the main study.

Related Conditions & MeSH terms

• Breast Cancer Female
• Breast Neoplasms

Intervention

Radiation:
• Mammogram
mammogram

Locations

Country	Name	City	State
United Kingdom	Wythenshawe Hospital	Manchester	Greater Manchester

Sponsors (1)

Lead Sponsor	Collaborator
Manchester University NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mammographic Density and Risk	To define the magnitude of BC risk associated with MD in women aged 30-39 and facilitate its incorporation into risk prediction models.	24 months
Primary	Psychological impact	To examine the feasibility of a strategy to offer breast cancer risk-assessment to diverse ethnic and socioeconomic populations of women in their 30s, assessing: Potential benefits and harms; Impact on health inequalities; Acceptability	24 months